Clinical Trials Directory

Trials / Suspended

SuspendedNCT02904304

Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold

Status
Suspended
Phase
Phase 3
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Ache Laboratorios Farmaceuticos S.A. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

National clinical trial, phase III, multicenter, randomized, prospective, double-blind, parallel, placebo-controlled, which one hundred and fifty (150) subjects of both sexes aged equal or more than 18 years will be randomly allocated to one the drug group or placebo group.

Detailed description

The investigational product is a combination of desloratadine, phenylephrine hydrochloride and ibuprofen. The desloratadine is a antihistamine and selectively block the activity of histamine receptor-1 (H1) resulting in a non sedative and prolong antiallergic effect. The phenylephrine is a potent stimulator of the postsynaptic α receptor with minimal effect on β receptors in the heart. The ibuprofen's mechanism is not fully known. It is a non selective inhibitor of cyclooxygenase, an enzyme that is involved in prostaglandin synthesis by the route from arachidonic acid. It is believed that the pharmacological effects are due to inhibition of cyclooxygenase-2 (COX-2), which reduces prostaglandin synthesis involved in the mediation of inflammation, pain, fever and swelling.

Conditions

Interventions

TypeNameDescription
DRUGDesloratadine+Phenylephrine+Ibuprofen01 tablet, orally, every 12 hours.
DRUGPlacebo01 tablet, orally, every 12 hours.

Timeline

Start date
2020-12-01
Primary completion
2021-07-01
Completion
2021-09-01
First posted
2016-09-16
Last updated
2019-07-08

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02904304. Inclusion in this directory is not an endorsement.